Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010
Links shared publicly online about this topic.
- 759total visits
Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010
Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.
View full resource at news-medical.net
Tags: Hepatitis B, Hepatitis B Medication, HIV, AIDS, HIV Medication, STD, Viread, News
Most Recently Shared on November 1, 2010 at 10:36 am By:
HIV/AIDS News: Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The ... http://bit.ly/9mkzyC
Advertisement
